These payloads block enzymes that help cells divide or read genes. An antibody may help deliver them to cancer cells that depend on those processes.
A cetuximab conjugate carrying SNS-032 was tested in EGFR-expressing triple-negative breast cancer cells, spheroids and xenograft models. SNS-032 inhibits CDK2, CDK7 and CDK9; it should not be described as a selective CDK9 payload. The study supports preclinical cell-cycle-directed delivery. A CDK inhibitor payload is also different from a degrader payload that removes a CDK protein.
Showing the technology this term belongs to: Antibody-drug conjugate (ADC).
Shares Transcription-inhibitor payloads, Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Transcription-inhibitor payloads, Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/